Carfilzomib (Kyprolis) combined with lenalidomide (Revlimid) and dexamethasone (Decadron; KRd) failed to improve progression-free survival (PFS), compared with the current standard of care triplet of bortezomib (Velcade), lenalidomide, and dexamethasone (VRd), in patients with newly diagnosed multiple myeloma, according to results of the ENDURANCE (E1A11) trial presented ahead of the 2020 ASCO Virtual Scientific Program.
As a result, researchers have determined that VRd remains the superior triplet induction regimen in this patient population, making it a suitable backbone for 4-drug combinations as well.
Given the higher efficacy of carfilzomib seen in recent phase II trials, investigators sought to determine if carfilzomib could replace bortezomib in the current standard of care triplet induction regimen in standard and intermediate risk newly diagnosed multiple myeloma.
To do so,…
